Semaglutide

What It Is

Semaglutide is a long-acting GLP-1 receptor agonist available as a weekly subcutaneous injection (Ozempic for diabetes, Wegovy for weight management) and an oral formulation (Rybelsus for diabetes, oral Wegovy approved March 2025 for weight management). In February 2026, the FDA approved Ozempic as the new proprietary name for oral semaglutide tablets at 1.5 mg, 4 mg, and 9 mg doses for type 2 diabetes — replacing Rybelsus with improved bioavailability tablets that became available in the US on May 4, 2026. The FDA also expanded semaglutide's kidney indications in January 2025, approving Ozempic to reduce the risk of kidney disease worsening and kidney failure in adults with type 2 diabetes and chronic kidney disease (FLOW trial: 24% risk reduction in major kidney events at 3 years). In Phase 3 EVOKE/EVOKE+ trials for early Alzheimer's disease, oral semaglutide did not slow clinical progression on CDR-SB or ADCS-ADL-MCI at 104 weeks versus placebo, though it significantly reduced CSF p-tau181 biomarker — suggesting biological effect on Alzheimer's pathology without clinical translation. It demonstrated approximately 15% weight loss at 68 weeks in pivotal obesity trials. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in overweight and obese adults without diabetes, fundamentally expanding GLP-1 agonists from diabetes medications to cardiovascular protectants. In 2026, multiple clinical trials are evaluating semaglutide's unexpected neuroprotective properties — particularly in Parkinson's disease research, where GLP-1 receptor agonism may slow disease progression by reducing neuroinflammation, enhancing mitochondrial function, and promoting neuronal survival in the substantia nigra. In a head-to-head NEJM trial, tirzepatide showed superior weight loss (−20.2% vs −13.7% for semaglutide at 72 weeks), though semaglutide retains advantages in approved indications, real-world prescribing data, and cardiovascular outcomes evidence. A large national cohort study published in The Lancet Psychiatry (2026) analyzing nearly 100,000 individuals from Swedish health registers found that GLP-1 receptor agonist use was associated with a 42% lower risk of worsening mental health outcomes, including a 44% lower risk of depression and 38% lower risk of anxiety, as well as a 47% lower risk of substance use disorder. GLP-1 RA users had significantly fewer psychiatric hospital visits and less time off work due to mental health conditions. While the study is observational and cannot establish causality, the magnitude of the associations — consistent across multiple psychiatric outcomes — has intensified research interest in GLP-1 receptor agonism as a potential neuropsychiatric intervention. In January 2026, the FDA approved oral semaglutide 25 mg (marketed as Wegovy) as the first-ever oral GLP-1 for weight management at $149/month, dramatically expanding access beyond injectable formulations. Oral semaglutide is also the first and only oral GLP-1 receptor agonist with an approved cardiovascular risk reduction indication, with the 7 mg and 14 mg tablets indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes. Additionally, Novo Nordisk reported positive PIONEER TEENS results in April 2026, demonstrating superior HbA1c reduction in children aged 10-17 with T2D, potentially making oral semaglutide the first oral GLP-1 RA for pediatric type 2 diabetes. Early real-world data from the first six weeks after oral Wegovy approval shows rapid uptake: 8,762 patients received prescriptions, with 36.1% having no prior GLP-1 use — indicating the oral formulation is expanding access to previously untreated patients. Most prescriptions were written by general practice providers rather than specialists, signaling mainstream adoption. Novo Nordisk's indirect comparison presented at the Obesity Medicine Association 2026 meeting showed oral Wegovy demonstrated greater weight loss than orforglipron with lower odds of discontinuation due to side effects. In August 2025, the FDA granted accelerated approval for Wegovy (semaglutide injection) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2-F3) -- making it the first GLP-1 receptor agonist approved for this indication. Approval was based on the Phase 3 ESSENCE trial, where 63% of semaglutide-treated patients achieved resolution of steatohepatitis with no worsening of fibrosis at 72 weeks versus 34% on placebo. Confirmatory data from the ongoing ESSENCE trial is required to verify long-term clinical benefit. On May 20, 2026, a systematic review and meta-analysis published in Cardiovascular Diabetology — Endocrinology Reports by Anglia Ruskin University researchers analyzed data from over 90,000 participants across major international clinical trials. The review confirmed that GLP-1 receptor agonists including semaglutide significantly reduce the risk of heart attacks, strokes, heart failure hospitalization, and cardiovascular death, with no meaningful increase in serious safety risks compared to placebo. This meta-analysis reinforces the SELECT trial's individual findings across a broader evidence base and strengthens the cardiovascular indication for semaglutide. Real-world comparative analyses published in 2026, including a propensity-matched cohort study, have associated GLP-1 receptor agonist use with approximately 20-35% lower dementia incidence compared to DPP-4 inhibitors or SGLT2 inhibitors, with the strongest effect observed for semaglutide. A 2026 AAN Annual Meeting presentation confirmed biomarker and real-world signals of neuroprotection in Alzheimer disease, while research published in the British Journal of Clinical Pharmacology demonstrated that the neuroprotective properties of GLP-1 receptor agonists correlate with their ability to cross the blood-brain barrier. These findings have intensified clinical interest in GLP-1 RA neurological applications, though large-scale randomized controlled trials specifically powered for dementia endpoints are still needed. At EASL Congress 2026 (May 27-30, Barcelona), Novo Nordisk presented new subgroup analyses from the ESSENCE Phase 3 trial demonstrating semaglutide's favorable hepatic safety profile independent of baseline patient characteristics, with dedicated analyses in menopausal women and Japanese patient populations — groups historically underrepresented in MASH research. The ESSENCE Liver Safety analysis, led by Philip Newsome, confirmed no hepatic safety signals regardless of age, sex, BMI, diabetes status, or baseline fibrosis stage. These data reinforce semaglutide's position as the first GLP-1 RA approved for MASH (August 2025), with growing real-world and subgroup evidence supporting its hepatic benefit profile. A landmark genome-wide association study by 23andMe Research Institute, published in Nature in April 2026, analyzed 27,885 GLP-1 medication users and identified a missense variant in GLP1R significantly associated with increased weight loss efficacy (additional −0.76 kg per copy of the effect allele). The study also found that variants in both GLP1R and GIPR are linked to nausea and vomiting side effects, with a partial loss-of-function variant in GIPR associated with increased vomiting risk exclusively in tirzepatide users but not semaglutide users. These findings lay the groundwork for genotype-informed prescribing in obesity pharmacotherapy and represent the first large-scale pharmacogenomic study of GLP-1 receptor agonist response. The Medicare GLP-1 Bridge program, launching July 1, 2026, covers both injectable Wegovy and oral Wegovy (tablets) for eligible Medicare Part D beneficiaries at a $50/month copayment — dramatically expanding access for the 67+ million Americans on Medicare. CMS has designated Wegovy (injection and tablets) alongside Foundayo and Zepbound as eligible medications under this time-limited demonstration running through December 31, 2027.

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Semaglutide compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Wilding JPH. et al. — Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021 PubMed
2. [2] OASIS 4 — Oral Semaglutide 25 mg in Adults with Overweight or Obesity. NEJM 2026 PubMed
3. [3] STEP UP — Semaglutide 7.2 mg in adults with obesity. Lancet Diabetes Endocrinol. 2026 PubMed
4. [4] Johns Hopkins — GLP-1 cardiovascular and kidney outcomes in type 1 diabetes. 2026 PubMed
5. [5] Stanford Medicine — GLP-1 resistance: PAM genetic variants reduce drug effectiveness. Genome Medicine, April 2026 PubMed
6. [6] Oral Wegovy vs orforglipron indirect treatment comparison — Obesity Medicine Association 2026 PubMed
7. [7] Genetic predictors of GLP-1 receptor agonist weight loss and side effects — Nature 2026 PubMed
8. [8] Repositioning GLP-1 Drugs for Neurologic Disease — NeurologyLive 2026 PubMed
9. [9] Repositioning GLP-1 Drugs for Neurologic Disease — NeurologyLive, April 2026 PubMed
10. [10] The expanding landscape of GLP-1 medicines — Nature Medicine 2026 PubMed
11. [11] Efficacy and safety of oral semaglutide 14 mg in early-stage Alzheimer's disease (EVOKE and EVOKE+): two phase 3 trials — The Lancet. March 2026 PubMed
12. [12] Comparative effectiveness of tirzepatide and semaglutide for obesity management — 6-month retrospective cohort study. PMC 2026 PubMed
13. [13] FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — FDA. May 2026 PubMed
14. [14] The Lancet Psychiatry — GLP-1 receptor agonist use associated with lower risk of worsening mental illness in depression and anxiety. 2026 PubMed
15. [15] Truveta — Early uptake of oral semaglutide for obesity (Wegovy pill). 2026 PubMed
16. [16] Novo Nordisk — Wegovy pill vs orforglipron indirect comparison at OMA 2026 PubMed
17. [17] FDA -- Approves Treatment for Serious Liver Disease Known as MASH (semaglutide). August 2025 PubMed
18. [18] Anglia Ruskin University — GLP-1 receptor agonists slash heart attack and stroke risk: meta-analysis of 90,000+ participants. Cardiovascular Diabetology — Endocrinology Reports. May 2026 PubMed
19. [19] Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort - PMC 2026 PubMed
20. [20] The neuroprotective properties of GLP-1R agonists correlate with their ability to cross the blood-brain barrier - PMC 2026 PubMed
21. [21] Novo Nordisk — Semaglutide ESSENCE Liver Safety and Subgroup Data at EASL 2026 PubMed
22. [22] Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature (2026) PubMed
23. [23] CMS — Medicare GLP-1 Bridge: $50/month coverage for Wegovy, Foundayo, and Zepbound beginning July 1, 2026 PubMed

Related Peptides